Mean IGF-I levels at the start of the core treatment phase suggest that the enrolled populations are comparable between the 2 trials—for example, the cohort is representative of acromegaly patients who were previously biochemically responding to iSRLs. This evidence concerns the gene IGF1 and acromegaly.